MMCM
IHE icon

Murphy & Mullick Capital Management’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Murphy & Mullick Capital Management’s Portfolio IHE Stock Details IHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-189
Closed -$13.3K – 683
2025
Q1 		$13.3K Hold
189
– – 0.01% 401
2024
Q4 		$12.4K Buy
+189
New +$13K 0.01% 406

Other funds holding IHE

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Murphy & Mullick Capital Management's IHE Position: Q2 2025 in Review

Murphy & Mullick Capital Management sold out of iShares US Pharmaceuticals ETF (IHE) in Q2 2025, closing a stake of 189 shares — an estimated $13.3K sold.

Murphy & Mullick Capital Management first reported a position in IHE in Q4 2024 and held it in 2 quarters. The position peaked at $13.3K in Q1 2025. 139 funds tracked by Wall St. Rank hold IHE as of Q2 2025.

  • Murphy & Mullick Capital Management reported no remaining iShares US Pharmaceuticals ETF position as of Q2 2025 after selling out during the quarter.
  • Murphy & Mullick Capital Management sold 189 iShares US Pharmaceuticals ETF shares in Q2 2025, an estimated $13.3K.
  • Murphy & Mullick Capital Management first reported a position in iShares US Pharmaceuticals ETF in Q4 2024 and held it in 2 quarters.
  • Murphy & Mullick Capital Management's iShares US Pharmaceuticals ETF position peaked at $13.3K in Q1 2025.
  • 139 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2025.

Based on Murphy & Mullick Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.